Pomalidomide-PEG3-C2-NH2 is primarily utilized in the field of medicinal chemistry and drug development, particularly in the design and synthesis of targeted therapies. Its structure combines pomalidomide, a known immunomodulatory agent, with a polyethylene glycol (PEG) linker and an amino group, making it a valuable component in the creation of antibody-drug conjugates (ADCs) and other targeted drug delivery systems. The PEG linker enhances solubility and reduces immunogenicity, while the amino group allows for further functionalization, enabling conjugation to antibodies, peptides, or other targeting moieties. This chemical is often employed in cancer research to develop therapies that specifically target cancer cells, minimizing damage to healthy tissues and improving therapeutic efficacy. Additionally, its application extends to the study of protein degradation mechanisms, particularly in the context of proteolysis-targeting chimeras (PROTACs), where it can be used to design molecules that selectively degrade disease-causing proteins.